Antimicrobial resistant pathogenes in nosocomial infections;Lekooporne drobnoustroje w zakażeniach szpitalnych

Postepy Mikrobiologii

Volumn 43, Issue 1, 2004, Pages 81-105

  Dzierzanowska, Danuta ^a   Pawińska, Alicja ^a   Kamińska, Wanda ^a   Patzer, Jan ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

CNSMR; ES L; Metallo laktamases; MRSA; VISA; VRE

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL METABOLISM; BACTERIUM ISOLATE; HOSPITAL INFECTION; HUMAN; NONHUMAN; RISK FACTOR;

BACTERIA (MICROORGANISMS);

EID: 2542485623     PISSN: 00794252     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (101)

1. Abraham E.P., Chain E.: An enzyme from bacteria able to destroy penicillin. Nature, 146, 837 (1940)
2. Afzal-Shah M., Woodford N., Livermore D.M.: Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumanii. Antimicrob. Agents Chemother. 45, 583-588 (2001)
3. Al-Obeid S., Billot-Klein D., Van Heijenoort J., Collatz E., Gutmann L.: Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBP's may explain vancomycin-beta-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366. FEMS Microb. Lett. 91, 79-84 (1992)
4. Ambler R.P.: The structure of β-lactamases. Philos. Trans. R. Soc. (London) Biol. 289, 321-331 (1980)
5. Arthur M., Courvalin P.: Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37, 1563-1571 (1993)
6. Arthur M., Molinas C., Depardieu F., Courvalin P.: Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 157, 117-127 (1993)
7. Belais S., Aubert D., Naas T., Nordmann P.: Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing β-lactamases in Chryseobacterium meningosepticum. Antimicrob. Agents Chemother. 44, 1878-1886 (2000)
8. Bennett P.M.: Molecular basis of β-lactamase induction in bacteria. Antimicrob. Agents Chemother. 37, 153-158 (1993)
9. Biavasco F., Vignaroli C., Varaldo P.F.: Glycopeptide resistance in coagulase-negative staphylococci. Eur. J. Clin. Microbiol. Infect. Dis. 19 (6), 403-17 (2000)
10. Billot-Klein D., Gutmann L., Collatz E.: Nucleotyde sequence of the SHV-5 β-lactamase gene of a Klebsiella pneumoniae plasmid. Antimicrob. Agents Chemother. 34, 2439-2441 (1990)
11. Bonomo R.A., Rudin S.A., Shiaes D.M.: Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamases. FEMS Microb. Lett. 148, 59-62 (1997)
12. Bou G., Cervero G., Dominguez M.A., Quereda C., Martinez-Beltran J.: Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumanii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumanii is not due solely to the presence of β-lactamases. Antimicrob. Agents Chemother. 44, 1556-1561 (2000)
13. Bradford P.A.: Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14, 933-951 (2001)
14. Bush K., Jacoby G.A., Medeiros A.A.: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39, 1211-1233 (1995)
15. Bush K.: Metallo-β-lactamases: a class apart. Clin. Infect. Dis. 27 (Suppl. 1), S48-S53, (1998)
16. rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, ASM, Washington, P76, (2003)
17. CDC. Interim guidelines for preventing and control of staphylococcal infections associated with reduced susceptibility to vancomycin. MMWR, 46, 626-628, 635 (1997)
18. CDC. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR, 51 (26), 565-567 (2002)
19. Chaibi E.B., Sirot D., Paul G., Labia R.: Inhibitor-resistant TEM-β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43, 447-458 (1999)
20. Cohen M.L.: Epidemiology of drug resistance: implications for a post-antimicrobial era. Science, 257, 1050-1055 (1992)
21. Courvalin P.: Preparing for battle against vancomycin resistance. Lancet, 347, 525 (1996)
22. Dzierżanowska D., Kamińska W.: Zastosowanie metod biologii molekularnej do wykrywania genów oporności na antybiotyki. Zakażenia, Nr 1, 24-33 (2003)
23. Dzierżanowska D., Murawska B., Pawińska A., Januszewicz P.: Wystȩpowanie MRSA i Gramujemnych pałeczek opornych na ceftazydym u dzieci przyjmowanych i hospitalizowanych w Instytucie Pediatrii Centrum Zdrowia Dziecka. II Ogólnopolskie Symp. Kierowniczej Kadry Medycznej "Profilaktyka i zwalczanie zakażeń szpitalnych", Warszawa, listopad 1997
24. Edmond M.B., Ober J.F., Weinbaum D.L., Pfaller M.A., Hwang T., Sanford M.D., Wenzel R.P.: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. 20, 1126-1133 (1995)
25. Von Eiff C., Peters G., Heilmann C.: Pathogenesis of infections due to coagulase-negative staphylococci. Lancet, 2, 677-85 (2002)
26. Eliopoulos G.M.: Vancomycin-resistant enterococci: mechanism and clinical relevance. Infect. Dis. Clin. North. Am. 11, 851-865 (1997)
27. Fleenor-Ford A., Hayden M.K., Weinstein R.A.: Vancomycin-resistant enterococci: Implications for surgeons. Surgery, 125, 121-125 (1999)
28. Fontana R., Ligoziti M., Pittaluga F., Satta G.: Intrinsic penicillin resistance in enterococci. Microb. Drug Res. 2, 209-213 (1996)
29. Gales A.C., Tognim M.C., Reis A.O., Jones R.N., Sader H.S.: Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumanii clinical strain from a Brazilian teaching hospital. Diagn. Microbiol. Infect. Dis. 45, 77-79 (2003)
30. Garbutt J., Ventrapragada M., Littenberg B., Mundy L.M.: Asociation between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin. Infect. Dis. 30, 466-472 (2000)
31. Ghuysen J.M.: Serine β-lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. 45, 37-67 (1991)
32. IMP-7. Antimicrob. Agents Chemother. 46, 255-258 (2002)
33. Gierczyński R., Szych J., Cieślik A., Rastawicki W., Jagielski M.: The occurrence of the first two CTX-M-3 and TEM-1 producing isolates of Salmonella enterica serovar Oranienburg in Poland. Int. J. Antimicrob. Agents, 21, 497-499 (2003)
34. Giske C.G., Rylander M., Kronvall G.: VIM-4 in a carbapenem-resistant strain of Pseudomonas aeruginosa isolated in Sweden. Antimicrob. Agents Chemother. 47, 3034-3035 (2003)
35. Gniadkowski M.: Ewolucja i epidemiologia szczepów pałeczek z rodziny Enterobacteriaceae wytwarzaja̧cych β-laktamazy o rozszerzonym spektrum substratowym (ESβL) w Polsce. Wyd. Ak. Med., Warszawa, praca habilitacyjna 2003
36. Goldman D.A., Weinstein R.A., Wenzel R.P.: Strategies to prevent control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA, 275, 234-240 (1996)
37. Gray J.W., Marsh J., Steward D., Pedler S.J.: Enterococcal bacteremia: a prospective study of 125 episodes. J. Hosp. Infect, 27, 179-186 (1994)
38. Van Griethuysen A., Veen A., Buiting A., Walsh T., Kluytmans J.: High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptidesin the Netherlands. J. Clin. Microbiol. 41, 2487-2491 (2003)
39. Hiramatsu K., Hanaki H., Ino T., Yabuta T., Oguri T., Tenover F.C.: Methicillin resistant Staphylococcus aureus clinical strains with reduced vancomycin susceptibility. J Antimicrob. Chemother. 40, 135-146 (1997)
40. Hooper D.V.: Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31 (Suppl. 2), S24-S28 (2000)
41. Kawalec M., Gniadkowski M., Hryniewicz W.: Outbreak of vancomycin-resistant enterococci in a hospital in Gdansk, Poland, due to horizontal transfer of different Tn1546-like transposon variants and clonal spread of several strains. J. Clin. Microbiol. 38, 9, 3317-3322 (2000)
42. Kaye K.S., Fraimow H.S., Abrutyn E.: Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect. Dis. Clin. N. Am. 14, 293-313 (2000)
43. Kȩdzierska J., Doleżal M., Kachlik P.: Ocena stanu oporności pałeczek Gram-ujemnych wyosobnionych z materiału klinicznego. Med. Dośw. Mikrobiol. 51, 113-122 (1999)
44. Kliebe C., Nies B.A., Meyer J.F.: Evolution of plasmid-coded resistance to broad spectrum cephalosporins. Antimicrob. Agents Chemother. 28, 302-307 (1985)
45. Knothe H., Shah P., Kromery V.: Transferable resistance to cefotaxime, cefoxitin, cefamandol and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection, 11, 315-317 (1983)
46. Krzysztoń-Russjan J., Gniadkowski M., Polowniak-Pracka H., Hagmajer E., Hryniewicz W.: The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland. J. Antimicrob. Chemother. 50, 1065-1069, (2002)
47. Kubler J.: Polisacharydy zewna̧trzkomórkowe gronkowców koagulazo-ujemnych i ich rola w chorobotwórczoś ci. Post. Hig. Med. Dośw. 52, 311-324 (1998)
48. Kurokawa H., Yagi T., Shibata N., Shibayama K., Arakawa Y.: Worlwide proliferation of carbapenem-resistant gra-negative bacteria. Lancet, 354, 955 (1999)
49. Lallemand S., Touverez M., Boisson K., Talon D., Bertrand X.: Bacteraemia caused by coagulase-negative staphylococci exhibiting decreased susceptibility to teicoplanin. J. Hosp. Infect. 51, 207-214 (2002)
50. Laudy A.E.: Karbapenemazy - enzymy moga̧ce hydrolizować szerokie spectrum β-laktamów. Zakażenia, Nr 4, 32-38 (2003)
51. VIM, a new integron-borne metallo-β-lactamase gene from Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43, 1584-1590 (1999)
52. Lautenbach E., Bilker W.B., Brennan P.J.: Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect. Control Hosp. Epidemiol. 20, 318-323 (1999)
53. Leclercq R., Courvalin P.: Resistance to glycopeptides in enterococci. Clin. Infect. Dis. 24, 545-556 (1997)
54. Li Z., Willke R.J., Pinto L.A., Littenhouse B.E., Rybak M.J., Pleil A.M., Crouch C.W., Hawkin B., Glick H.A.: Comparision of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus sp. infections treated with linezolid or vancomycin: a randomized multicenter trial. Pharmacothetapy, 21 (2), 263-74 (2001)
55. Livermore D.M., Woodford N.: Carbapenemases: a problem is waiting? Curr. Opin. Microbiol. 3, 489-495 (2000)
56. Livermore D.M.: β-lactamases in laboratory and clinical resistance. Clin. Microb. Rev. 8, 557-584 (1995)
57. Livermore D.M.: Quinupristin/dalfopristin and linezolid: were, when, which and whether to use? J. Antimicrob. Chemother. 46, 347-350 (2000)
58. Lopez-Otsoa F., Gallego L., Towner K.J., Tyssal L., Woodford N., Livermore D.M.: Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumanii isolates from a hospital in northern Spain. J. Clin. Microbiol. 40, 4741-4743 (2002)
59. Lucas G., Lechtzin N., Puryear W., Yau L., Flexner C., Moore R.: Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin. Infect. Dis. 26, 1127-1133 (1998)
60. McManus J.: Vancomycin resistant staphylococcus reported in Hong Kong. BMJ, 318, 626 (1999)
61. Medeiros A.A.: β-Lactamases. Br. Med. Bull. 40, 18-27 (1985)
62. Megran D.W.: Enterococcal endocarditis. Clin. Infect. Dis. 15, 63-71 (1992)
63. Młynarczyk G., Rosdahl V.T., Skov R., Młynarczyk A.: Epidemiology of methicillin resistant Staphylococcus aureus in a Warsaw hospital. J. Hosp. Infect. 34, 151-160 (1996)
64. Mundy L.M., Sahm D.F., Gilmore M.: Relationships between enterococcal virulence and antimicrobial resistance. Clin. Microbiol. Rev. 13, 4, 513-522 (2000)
65. Murphy T.A., Simm A.M., Toleman M.A., Jones R.M., Walsh T.R.: Biochemical characterization of the aquired metallo-β-lactamase SPM-1 from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 47, 582-587 (2003)
66. National Nosocomial Infections Surveillance System Report: data summary from January 1990-May 1999. Atlanta: Hospital Infections program, National Center for Infectious Diseases, Centers for Disease Control and prevention, Public health Service, US Department of Health and Human Services, 1999
67. Noble W.C., Viarani Z., Cree R.: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 93, 195-198 (1992)
68. Nordmann P., Poirel L.: Emerging carbapenemases in gram-negative aerobes. Clin. Microbiol. Infect. 8, 321-331 (2002)
69. O'Grady N. P.: Guideline for the prevention of intravascular catheter-related infections. Pediatrics. 10, 1-24 (2002)
70. Paton R., Miles R.S., Hood J., Amyes S.G.B.: ARI-1: β -lactamase-mediated imipenem resistance in Acinetobacter baumanii. Int. J. Antimicrob. Agents, 2, 81-88 (1993)
71. Patzer J., Dzierżanowska D., Turner P.: Susceptibility patterns of Gram-negative bacteria from a Polish intensive care unit, 1997-2000. Int. J. Antimicrob. Agents, 19, 431-434 (2002)
72. VIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). J. Antimicrob. Chemother. (w druku)
73. Pawińska A., Łopaciuk U., Semczuk K., Dzierżanowska D.: Wykorzystanie metod biologii molekularnej w ocenie podobieństwa gronkowców koagulazo-ujemnych izolowanych z sekwencyjnych posiewów krwi. Ped. Pol. 11, 919-28. (2002)
74. Pawińska A: Oporność na wankomycynȩ u Staphylococcus aureus. Zakażenia, Nr 2, 89-96 (2003)
75. Pawińska A.: Udział gronkowców koagulazo-ujemnych w etiologii szpitalnych posocznic. Zakażenia, Nr 2, 125-128 (2003)
76. Petit A.: Molecular epidemiology of TEM-3 (CTX-1) β-lactamase. Antimicrob. Agents Chemother. 34, 219-224 (1990)
77. Poirel L., Heritier C., Podglajen I., Sougakoff W., Gutman L., Nordmann P.: Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV β-lactamase that comprises the efficacy of imipenem. Antimicrob. Agents Chemother. 47, 755-758 (2003)
78. Poirel L., Naas T., Nicolas D., Collet L., Bellais S., Cavallo J.D., Nordmann P.: Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44, 891-897 (2000)
79. VIM-4. J Antimicrob. Chemother. 51, 1409-1414 (2003)
80. VIM-1 in a clinical strain of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 46, 4026-4028 (2002)
81. Raney P.M., Williams P.P., McGowan J.E., Tenover F.C.: Validation of Vitek version 7.01 software for testing staphylococci against vancomycin. Diagn. Microbiol. Infect. Dis. 43, 135-40 (2002)
82. Rasmussen B.A., Bush K.: Carbapenem-hydrolyzing β-lactamase. Antimicrob. Agents Chemother. 41, 223-232 (1997)
83. Sabath L.D., Abraham E.P.: Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem. J. 98, 11c-13c (1966)
84. Sanders C.C.: β-lactam resistance in gramnegative bacteria: global trends and clinical impact. Clin. Infect. Dis. 15, 824-839 (1992)
85. Schaberg D.R., Culver D.H., Gaaynes R.P.: Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91 (suppl.3B), 72S-75S (1991)
86. Senda K., Arakawa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K., Kato N., Ohta M.: Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob. Agents Chemother. 40, 349-353 (1996)
87. Smith T.L., Pearson M.L., Kenneth R.: Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340, 493-501 (1999)
88. Srinivasan A., Dick J.D., Perl T.M.: Vancomycin resistance in staphylococci. Clin. Microbiol. Rev. 15, 430-438 (2002)
89. Swalbe R.S., Ritz W.J., Werma P.R., Barranco E.A., Gilligan P.H.: Selection of vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J. Infect. Dis. 161, 45-51 (1990)
90. Tassios P.T., Gazoull M., Tzelepi E. et al.: Clonally related cefotaxime-resistant Salmonella typhimurium isolates from Greece, Russia and Hungary. Clin. Microbiol. Infect. 5 (Suppl. 3), 75-76 (1999)
91. Tenover F.C., Mohammed M.J., Gorton T.S., Dembek Z.F.: Detection and reporting of organisms producing extended-spectrum β-lactamases: survery of laboratories in Connecticut. J. Clin. Microbiol. 37, 4065-4070 (1999)
92. Toleman M.A., Biedenbach D., Bennett D., Jones R.N., Walsh T.R.: Genetic characterization of a novel metallo-beta-lactamase gene bla IMP-13, harboured by a novel Tn5051-type transposon disseminating carbapenemase genes in Europe: report from the SENTRY worldwide antimicrobial surveillance programme. J. Antimicrob. Chemother. 52, 583-590 (2003)
93. Toleman M.A., Rolston K., Jones R.N., Walsh T.R.: blaVIM-7, an evolutionarily distinct metallobeta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 48, 329-332 (2004)
94. Toleman M.A., Simm A.M., Murphy T.A., Gales A.C., Biedenbach D.J., Jones R.N., Walsh T.R.: Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J. Antimicrob. Chemother. 50, 673-679 (2002)
95. Tracolsomboon S., Danchaivijitr S., Rongrungruang Y., Dhiraputra C., Susaemgrat W., Ito T., Hiramatsu K.: First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J. Clin. Microbiol. 39, 591-595 (2001)
96. Trzciński K., Tyski S., Zarȩba T., Hryniewicz W.: Oporność na chemioterapeutyki ważnych klinicznie bakterii izolowanych w Polsce w latach 1994-1995. Mikrobiol. Med. 4, 64-71 (1996)
97. Vincent J.L., Bihari D.J., Suter P.M., Bruining H.A.: For the EPIC International Advisory Committee: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. JAMA, 274, 639-644 (1995)
98. VIM-2 in Eastern Europe: report from the SENTRY antimicrobial surveillance programme. J. Antimicrob. Chemother. 52, 116-119 (2003)
99. Watanabe M., Iyobe S., Inoue M., Mitsuhashi S.: Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 35, 147-151 (1991)
100. Wernwer G., Cuny C., Schmitz F-J., Witte W.: Methicilin-resistant quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J. Clin. Microbiol. 39, 3586-3590 (2001)
101. Zeckel M.L.: Bliższe spojrzenie na wankomycynȩ, teikoplaninȩ i oporność drobnoustrojów. Zakażenia, Nr 2, 3-13 (1998)